Cancer Network

The November issue of ONCOLOGY features a wide range of articles from those focused on survivorship, multiple myeloma and pleural effusion, and gender equity. Read the full issue here: https://lnkd.in/ezUxzfWB

View our top 5 articles of the week: 1. https://lnkd.in/ezkWB3jM 2. https://lnkd.in/eugFc9Fw 3. https://lnkd.in/eUnBfK3y 4. https://lnkd.in/eBkV4c9i 5. https://lnkd.in/eh-ZjgEn

Personalized therapy for non–small cell lung cancer has evolved significantly with the advent of comprehensive molecular testing. https://lnkd.in/esM-HBMg #NSCLC #cancer #oncology

An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well. https://lnkd.in/edW6vhqR #lcsm #cancer #oncology

Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy. Rutgers Cancer Institute https://lnkd.in/e7BmhU8s #hematology #cancer #oncology

Want to learn the latest on: ⚫️ 177-Lu Dotatate for NETs ⚫️ Lifestyle Medicine for Survivorship ⚫️Uterine Transposition Surgery ⚫️NP Tips and Tricks for Talquetamab-Related AEs Read the November issue of ONCOLOGY available now! https://lnkd.in/ezUxzfWB

Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors. Rutgers Cancer Institute https://lnkd.in/es_eudDG #cancer #oncology

Health First, Central Florida’s premier health system, is expanding its team and seeking a hematology/oncology specialist. Enjoy a great work-life balance with a schedule of 4 clinic days and 1 admin day, Monday through Friday (8:30 a.m. - 4:30 p.m.), and 1:4 call coverage. Position Highlights: 1. Robust infusion center 2. Referral network of 500+ providers from Health First 3. Highly competitive salary & benefits package Requirements: • Board-certified or board-eligible in Hematology/Oncology Ready to make an impact on the space coast? Apply here: https://ow.ly/MaOC50UfUrK #HematologyOncology #SpaceCoastFlorida #HealthFirstCareers

Panelists discuss how IDH inhibitors such as ivosidenib could potentially reshape the treatment approach for low-grade gliomas. https://lnkd.in/eDy6j94x #btsm #cancer #oncology

Panelists discuss how the interpretation of HER2 IHC scores informs treatment decisions in NSCLC, including adherence to ASCO/CAP guidelines and strategies for managing equivocal results. https://lnkd.in/eDWsWFYd #NSCLC #cancer #oncology